We're excited to unveil our new HCmed UK site, located in Chichester, West Sussex UK.

HCmed announced the appointment of Gunilla Petersson, Ph.D. as the new Chief Scientific Officer (CSO).

Dr. Shao Chi Huang this month shares his experience working in the clinical field.

HCmed Innovations Co., Ltd. (6934) is pleased to announce that it has recently become a public company in Taiwan.

Finance and Accounting Manager of the Management Department at HCmed Innovations, Wooca Tu, this week shares his working experience and management goals at HCmed.

We are excited to announce that HCmed will join the Drug Delivery to the Lungs (DDL) 2023 Conference.

We are excited to announce that HCmed will join the North American Cystic Fibrosis Conference (NACFC) 2023.

Join HCmed Innovations at the Medical Fair Thailand 2023 to learn about the features and advantages of our Pulmogine Vibrating Mesh Nebulizer.

Join HCmed Innovations at the ERS 2023 International Congress to explore collaborations with pharmaceutical companies looking for partnership to develop drug-nebulizer combination products.

We are excited to announce that HCmed will join the American Thoracic Society (ATS) 2023 Conference

The HCmed's team describes the value that customisable nebuliser platforms bring to patient adherence

The overall scope of the study presents the benefits of an exploratory work at the development stage of a new drug-nebuliser combination product, aiming to identify the most suitable pair for the targeted delivery requirements.

The HCmed's team looks at the advantages of customisable nebuliser platforms for new combination products

The investigations revealed the potential efficacy of IFN-β in the treatment of IPF with the mesh nebulizer, demonstrating the higher efficiency of IFN-β delivered through the mesh nebulizer.

HCmed Innovations considers patient adherence and the role the company's mesh nebuliser places in monitoring it

心誠鎂行動醫電公司今（3）日宣布，將與美國AeroRx Therapeutics公司合作開發一款透過呼吸驅動霧化器，用來遞送LABA/LAMA 複方藥物用於治療慢性肺阻塞（COPD），雙方也同時確認未來後續的合作內容與架構。

AeroRx Therapeutics, LLC. (AeroRx) and HCmed Innovations Co., Ltd. (HCmed) have initiated a collaboration, introducing a LABA/LAMA combination solution for delivery with a breath-actuated nebulizer.

心誠鎂30日宣布，該公司B輪募資，超額認購200％，共取得資金600萬美元（約1.8億台幣），並吸引台耀（4746）和安瑞投資成為新股東。

心誠鎂行動醫電公司今（7）日宣布，該公司與台耀化學、台新藥三公司已於2 月簽署合作備忘錄，三方看準全球呼吸治療藥物需求強勁，將串聯心誠鎂之醫用霧化器，台耀之藥物開發生產服務，以及台新藥APNT奈米技術平台組成聯盟，合作推廣CDMO業務為國際藥廠客戶提供一站式服務。

HCmed announced that it has formed a strategic alliance with Formosa Laboratories and Formosa Pharmaceuticals to expand its business in the inhalation treatment field, providing contract development and manufacturing services.